secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001493152-25-001704
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eterna receives Nasdaq delisting notice for low MVLS; board changes
-------------------------------------------------------------------

- Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.
- Company has 180-day cure period (until July 7, 2025) to regain compliance with MVLS standard.
- Director Dorothy Clarke resigned Jan 6, 2025; no disagreement with Company; remains general counsel.
- Dr. Elena Ratner appointed to Board effective Jan 7, 2025; determined independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer